Official Title: “A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model”

The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.

Study Type: Interventional

Study Design: Randomized, Double Blind (Subject, Investigator), Parallel Assignment

Study Primary Completion Date: January 2008

Intervention(s) in this Clinical Trial

• Drug: Epinastine HCl
• Drug: Olopatadine HCl

Primary Measures

• Change in ocular itch score from baseline
  • Time Frame: 1 day
    

Secondary Measures

• Ocular comfort score
  • Time Frame: 1 day
    

Inclusion Criteria:

• Documented history of ocular allergy to cats.
• Positive skin prick allergen reaction to cat dander.

Exclusion Criteria:

• Use of any topical or systemic corticosteroids, immunosuppressive agents, antihistamines, decongestants, NSAIDs, or asprin during the two weeks prior to enrollment into the study.
• History of severe asthma, reactive airway disease or bronchial obstruction.
• Ocular surgery or trauma in the last year.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Lead Sponsor: Inspire Pharmaceuticals

Overall Clinical Trial Officials and Contacts

Michael Raizman, MD Principal Investigator Ophthalmic Consultants of Boston  

Information obtained from ClinicalTrials.gov on January 08, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00534794

Study ID Number: 031-408

ClinicalTrials.gov Identifier: NCT00534794

Health Authority: United States: Institutional Review Board